<DOC>
	<DOCNO>NCT00095186</DOCNO>
	<brief_summary>The purpose study determine orally-administered recombinant human lactoferrin effective treatment advance renal cell carcinoma ( RCC ) patient fail least one prior systemic therapy RCC .</brief_summary>
	<brief_title>Safety/Efficacy Study Oral Recombinant Human Lactoferrin Renal Cell Carcinoma</brief_title>
	<detailed_description>This open label , multi-center Phase 2 study . Approximately 40 patient enrol single study arm . RhLF , dose 1.5 g [ 1 vial ] , twice day ( b.i.d . ) , administer orally two cycle 12 consecutive week follow 2 week . A maximum two additional cycle may give objective response obtain patient stable disease increase size target tumor ( ) relative either Screening CT recent CT measurement , measure accord RECIST prior additional cycle ( ) . Response progression-free survival evaluate first 20 patient enrol . If patient objective response le 10 % patient alive progression-free 14 week start Study Drug , study terminate . If either Cycle 3 Cycle 4 , three first ten patient six first twenty patient enter cycle experience Grade 3 4 Study-Drug-related adverse event , patient advance Cycle 3 Cycle 4 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Age ≥18 year Histologically confirm , advance metastatic RCC predominantly clear cell histology unresectable medically inoperable . Experienced fail least one regimen systemic therapy RCC CT documentation disease progression . A previous CT ( 4 week prior Screening CT ) show progression target tumor ( ) compare prior CT 9 month previously At least one target tumor lesion measurable Screening CT scan , accord RECIST , previously irradiate Karnofsky performance status ≥70 ( ECOG &lt; 2 ) Able understand sign inform consent Significant sarcomatoid , spindle cell , nuclear grade 4 histology Significant nonclear cell RCC ( example , papillary , chromophobe , collect duct , granular , unclassified RCC ) Total bilirubin &gt; 1.5 mg/dL Serum creatinine &gt; 2.0 mg/dL Hemoglobin &lt; 10.0 g/dL Absolute neutrophil count &lt; 2000/mm3 Lymphocytes &lt; 800/mm3 Platelet count &lt; 100,000/mm3 AST ( SGOT ) ALT ( SGPT ) ≥2.5 x institutional upper limit normal Serum calcium &gt; 11.5 mg/dl International Normalized Ratio Prothrombin Time ( INR ) &gt; 1.2 FEV1 &lt; 60 % predict FVC &lt; 60 % predict spirometry ( measure ) Existing history brain metastasis History allergic reaction compound similar chemical biologic composition Study Agent rhLF Active ischemic heart disease , symptomatic congestive heart failure Serious active infection Psychiatric illness/social situation would limit compliance study requirement Autoimmune disease ( e.g. , systemic lupus erythematosus , multiple sclerosis ankylose spondylitis ) Other malignancy , except nonmelanoma skin cancer , within 5 year study entry Radiotherapy within 4 week prior study treatment start Corticosteroid therapy within 4 week prior treatment start , exception inhale topical steroid Chemotherapy/Immunotherapy ( e.g. , IL2 , INFα , tumor vaccine ) within 4 week prior study treatment start Known HIV positive Receipt investigational medication within 30 day prior participation study Pregnant lactating patient , fertile female patient positive pregnancy test ( serum βhuman chorionic gonadotropin [ βHCG ] Screening Day 1 prior first dose ) , fertile female patient unwilling use adequate contraception prior study entry , treatment 30 day completion treatment Sexually active male patient unwilling practice contraception participate study 30 day completion treatment Unable take liquid medication mouth feed tube</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Kidney</keyword>
	<keyword>Refractive</keyword>
	<keyword>Lactoferrin</keyword>
	<keyword>Oral</keyword>
</DOC>